Aurobindo Pharma Q4 Profit Slips Marginally to ₹903 Crore

26 May 2025 , 09:14 PM

Aurobindo Pharma Ltd. on Wednesday recorded a dip in its consolidated profit after tax (PAT) to post ₹903 crore for the fourth quarter ended March 31, 2025 as against ₹907 crore in the corresponding quarter in 2014-15.

The company posted robust topline growth for the March quarter, with total revenue from operations increasing to ₹8,382 crore from ₹7,580 crore in Q4 FY24.

On a fiscal year basis (FY25), Aurobindo Pharma’s PAT increased 10% y-o-y to ₹3,484 crore from ₹3,169 crore in FY24, showing better full year profitability. Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis.

“As our May sales and EBITDA performance is the highest ever for both a quarter as well as for the full year, this performance in May due to the strong demand we see across our core units and product mix,” Vice-Chairman and Managing Director K. Nithyananda Reddy said. The firm attributed its sustainable momentum to its steady volume-driven growth and its differentiated portfolio strategy during the fiscal.

Aurobindo’s performance in Europe also remained strong, as the region was on course to achieve $1 Billion in annual revenue, thus strengthening the company’s presence in the world. Management commented that the continued capacity expansions will facilitate future scalability, improve market compete, and support long-term value creation for shareholders.